The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 361:193-195 July 9, 2009 Number 2
NextNext

Gene Therapy — Still a Work in Clinical and Regulatory Progress
Elizabeth L. Hohmann, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Frank, K. M.
-PubMed Citation
In this issue of the Journal, Frank and colleagues present the case history and autopsy results of a widely publicized death in the summer of 2007 of a young woman who was taking part in a Phase 1–2 gene-therapy study of rheumatoid arthritis.1 Although the patient's death was initially attributed by some to the intraarticular gene therapy, because of a striking temporal association, the adeno-associated virus (AAV) vector appears now to be exonerated. The death is most reasonably attributed to disseminated, recrudescent infection with Histoplasma capsulatum, an environmental fungus that is present primarily, but not exclusively, in the midwestern United . . . [Full Text of this Article]


Source Information

From the Partners Human Research Committees, Boston.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.